Aktuellt
SENASTE
Redeye provides a research update in regards to the Q3 report published by Alzinova earlier today. Overall, the report was in line with our expectations. However, the main focus right now is the upcoming readout form the crucial phase Ib study with ALZ-101. For now, as we await the study results, we reiterate our previous fair value range (SEK1 – SEK20) with a base case valuation of SEK10.
LÄS MER
